Navigation Links
Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads
Date:6/17/2011

SHAWNEE, Kan., June 17, 2011 /PRNewswire/ -- Bayer HealthCare LLC announced today that it has reached a successful resolution of the lawsuit between Bayer and Farnam Companies Inc. over Farnam's advertising for its Bio Spot® flea and tick control products.  As part of the settlement, Farnam has agreed to withdraw the challenged advertising.

Farnam's print and online advertising campaign included claims that Bio Spot® was "as effective as popular vet brands," that Bio Spot® was "the best flea and tick control available," and that Bio Spot® was "the choice of professionals."  Farnam did not have any head-to-head clinical studies supporting its claims that its products were superior to, or as effective as, Bayer's premium flea and/or tick control products Advantage® II and K9 Advantix® II.  Bayer argued in a challenge submitted to the National Advertising Division of the Council of Better Business Bureaus (or NAD) that Farnam's advertising claims were false and unsubstantiated; Farnam responded by filing a lawsuit in the United States District Court for the District of Arizona seeking a declaration that its advertising was not false.

Today's settlement announcement ends both the NAD challenge and federal lawsuit.  As part of the settlement, Farnam has agreed to discontinue all of the advertising claims challenged by Bayer, and will refrain from making similar unsupported claims in future advertising.  Farnam will be given a short transition period to make the necessary changes to all of its advertising materials.

Bayer was represented by David H. Bernstein and Christopher Hamilton of Debevoise & Plimpton LLP, and Nicole Goodwin of Quarles & Brady LLP.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions.  Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.

With sales of EUR 1,120 million (2010), Bayer's Animal Health business is one of the world's leading manufacturers of veterinary drugs. The division manufactures and markets approximately 100 different veterinary drugs and care products for food-supplying animals and companion animals. U.S. Headquarters for Bayer Animal Health is located in Shawnee, Kansas.  Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayers Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
2. Bayers Discrimination Lawsuit Now Requires Extra-Strength Cure
3. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Bayer HealthCare to Sponsor World Federation of Hemophilia Global Training Program and Donate Kogenate® FS, Antihemophilic Factor (Recombinant), Commercially Valued At More Than $7 Million
5. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
6. Two New Studies in the British Medical Journal Find That Bayers Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot
7. Bayer Launches First Interactive Virtual Walk in Support of Hemophilia
8. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
9. Bayer HealthCare Selects the State of New Jersey for East Coast Site Consolidation
10. Bayer Gets $100M Gender Class Action Headache
11. TV Personality Vanessa Minnillo Teams Up With Bayer and March of Dimes to Launch National Folate Awareness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):